CDC: Cancer death rates drop while heart disease deaths rise in the U.S.

Two of the leading causes of death have had opposite trajectories in the U.S. over the last two decades, despite sharing similar lifestyle and health-risk factors. Cancer death rates have dropped 19% in the U.S. from 1999 to 2017, while heart disease death rates saw an initial drop of 22% from 1999, they increased 4% from 2011 to 2017, according to the Centers for Disease Control and Prevention (CDC).

The agency outlined the death rate trends for both cancer and heart disease from 1999 to 2017 among middle-age adults between 45 and 64, noting that the two are among the top killers in the nation and have several of the same underlying causes and risks, including obesity, diabetes, hypertension and tobacco use.

The decline in cancer death rates was greater between 1999 and 2007 and 2014 to 2017, about 1.5% annually during those years, compared to 0.5% from 2007 to 2014. By comparison, heart disease death rates dropped, but then rose again, meaning that by 2017 the rate was 19% lower than in 1999. Cancer death rates have always historically been higher than heart disease, and were 37% higher in 2017, the CDC found.

Both men and women saw similar patterns in decline for both cancer and heart disease over the last two decades, and both saw a pattern of increase in heart disease death rates more recently. Non-Hispanic white women saw the greatest increase in heart disease death rates by gender and ethnicity, at 12%. Over the same time period, Hispanic women and men experienced an initial decline before heart disease death rates leveled off.

See the full report here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.